Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

Hans J J van der Vliet; Johan W Molling; B Mary E von Blomberg; Wendy Kölgen; Anita G Stam; Tanja D de Gruijl; Chris J Mulder; Harry L A Janssen; Nobusuke Nishi; Alfons J M van den Eertwegh; Rik J Scheper; Carin J M van Nieuwkerk

doi:10.1016/j.clim.2004.10.001

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

Hans J J van der Vliet, Johan W Molling, B Mary E von Blomberg, Wendy Kölgen, Anita G Stam, Tanja D de Gruijl, Chris J Mulder, Harry L A Janssen, Nobusuke Nishi, Alfons J M van den Eertwegh, Rik J Scheper, Carin J M van Nieuwkerk

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). Previous studies have indicated that alpha-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Valpha24+Vbeta11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Valpha24+Vbeta11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Valpha24+Vbeta11+ NKT cell ligand alpha-GalCer in HCV-infected patients are present.

Original language	English
Pages (from-to)	183-189
Number of pages	7
Journal	Clinical Immunology
Volume	114
Issue number	2
DOIs	https://doi.org/10.1016/j.clim.2004.10.001
Publication status	Published - Feb 2005

Access to Document

10.1016/j.clim.2004.10.001

Embargoed Document

188770
Final published version, 284 KB

Cite this

van der Vliet, H. J. J., Molling, J. W., von Blomberg, B. M. E., Kölgen, W., Stam, A. G., de Gruijl, T. D., Mulder, C. J., Janssen, H. L. A., Nishi, N., van den Eertwegh, A. J. M., Scheper, R. J., & van Nieuwkerk, C. J. M. (2005). Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clinical Immunology, 114(2), 183-189. https://doi.org/10.1016/j.clim.2004.10.001

van der Vliet, Hans J J ; Molling, Johan W ; von Blomberg, B Mary E ; Kölgen, Wendy ; Stam, Anita G ; de Gruijl, Tanja D ; Mulder, Chris J ; Janssen, Harry L A ; Nishi, Nobusuke ; van den Eertwegh, Alfons J M ; Scheper, Rik J ; van Nieuwkerk, Carin J M. / Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. In: Clinical Immunology. 2005 ; Vol. 114, No. 2. pp. 183-189.

@article{3a18a3d5f8b6453f9bb3ad414b2e1446,

title = "Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients",

abstract = "CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). Previous studies have indicated that alpha-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Valpha24+Vbeta11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Valpha24+Vbeta11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Valpha24+Vbeta11+ NKT cell ligand alpha-GalCer in HCV-infected patients are present.",

keywords = "Adult, Aged, Aged, 80 and over, Antigens, CD1/biosynthesis, Antigens, CD1d, Antiviral Agents/therapeutic use, Cohort Studies, Cross-Sectional Studies, Dendritic Cells/immunology, Female, Flow Cytometry, Hepacivirus/immunology, Hepatitis C/drug therapy, Humans, Immunophenotyping, Interferon-alpha/therapeutic use, Killer Cells, Natural/immunology, Longitudinal Studies, Male, Middle Aged, Polyethylene Glycols, RNA, Viral/blood, Recombinant Proteins, Ribavirin/therapeutic use, T-Lymphocyte Subsets/immunology",

author = "{van der Vliet}, {Hans J J} and Molling, {Johan W} and {von Blomberg}, {B Mary E} and Wendy K{\"o}lgen and Stam, {Anita G} and {de Gruijl}, {Tanja D} and Mulder, {Chris J} and Janssen, {Harry L A} and Nobusuke Nishi and {van den Eertwegh}, {Alfons J M} and Scheper, {Rik J} and {van Nieuwkerk}, {Carin J M}",

year = "2005",

month = feb,

doi = "10.1016/j.clim.2004.10.001",

language = "English",

volume = "114",

pages = "183--189",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

van der Vliet, HJJ, Molling, JW, von Blomberg, BME, Kölgen, W, Stam, AG , de Gruijl, TD , Mulder, CJ, Janssen, HLA, Nishi, N, van den Eertwegh, AJM , Scheper, RJ & van Nieuwkerk, CJM 2005, 'Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients', Clinical Immunology, vol. 114, no. 2, pp. 183-189. https://doi.org/10.1016/j.clim.2004.10.001

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. / van der Vliet, Hans J J; Molling, Johan W; von Blomberg, B Mary E; Kölgen, Wendy; Stam, Anita G ; de Gruijl, Tanja D ; Mulder, Chris J; Janssen, Harry L A; Nishi, Nobusuke; van den Eertwegh, Alfons J M ; Scheper, Rik J; van Nieuwkerk, Carin J M.

In: Clinical Immunology, Vol. 114, No. 2, 02.2005, p. 183-189.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

AU - van der Vliet, Hans J J

AU - Molling, Johan W

AU - von Blomberg, B Mary E

AU - Kölgen, Wendy

AU - Stam, Anita G

AU - de Gruijl, Tanja D

AU - Mulder, Chris J

AU - Janssen, Harry L A

AU - Nishi, Nobusuke

AU - van den Eertwegh, Alfons J M

AU - Scheper, Rik J

AU - van Nieuwkerk, Carin J M

PY - 2005/2

Y1 - 2005/2

N2 - CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). Previous studies have indicated that alpha-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Valpha24+Vbeta11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Valpha24+Vbeta11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Valpha24+Vbeta11+ NKT cell ligand alpha-GalCer in HCV-infected patients are present.

AB - CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). Previous studies have indicated that alpha-GalCer-induced activation of the immune system requires both CD1d expression by antigen-presenting cells as well as (normal) numbers of NKT cells. Discrepancies exist over circulating numbers of human invariant Valpha24+Vbeta11+ NKT cells during hepatitis C virus (HCV) infection. Here, by cross-sectional analysis and longitudinal analysis of patients undergoing effective combination antiviral therapy, we demonstrate that circulating Valpha24+Vbeta11+ NKT cell numbers are not decreased during active HCV infection. Importantly, as we also show that CD1d is expressed at comparable levels by peripheral blood monocytes and CD1c+ myeloid dendritic cells (DC) of healthy individuals and HCV-infected patients, these data indicate that all ingredients for evaluating the antiviral effects of the Valpha24+Vbeta11+ NKT cell ligand alpha-GalCer in HCV-infected patients are present.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antigens, CD1/biosynthesis

KW - Antigens, CD1d

KW - Antiviral Agents/therapeutic use

KW - Cohort Studies

KW - Cross-Sectional Studies

KW - Dendritic Cells/immunology

KW - Female

KW - Flow Cytometry

KW - Hepacivirus/immunology

KW - Hepatitis C/drug therapy

KW - Humans

KW - Immunophenotyping

KW - Interferon-alpha/therapeutic use

KW - Killer Cells, Natural/immunology

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Polyethylene Glycols

KW - RNA, Viral/blood

KW - Recombinant Proteins

KW - Ribavirin/therapeutic use

KW - T-Lymphocyte Subsets/immunology

U2 - 10.1016/j.clim.2004.10.001

DO - 10.1016/j.clim.2004.10.001

M3 - Article

C2 - 15639652

VL - 114

SP - 183

EP - 189

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -